Cover Page for Protocol 
Sponsor name:  [CONTACT_3454] A/S 
NCT number [STUDY_ID_REMOVED] 
Sponsor trial ID: NN2211-4232 
Official title of study: LIRA-PRIME: Ef ficacy in controlling glycaemia with 
Victoza® (liraglutide) as add-on to metformin vs. OADs as add-on to metformin after up to  104 weeks of treatment in 
subjects with type 2 diabetes inadequately controlled with 
metformin monotherapy and treat ed in a primary care setting 
Document date: [ADDRESS_849119] of contents
Protocol ....................................................... ............................................................... .........................
Protocol Amendment 01 - Global......................................................... .............................................
Protocol Amendment 02 - US............................................................. ...............................................CONFIDENTIALDate: Novo Nordisk
Version:
Status:/LUDJOXWLGH
Trial ID:NN2211-4232 
Clinical Trial Report 
Appendix 16.1.1 January 2020
1.0
Final
16.1.1 Protocol and protocol amendmentsCONFIDENTIAL
 
 
 
 
 
Redacted protocol 
Includes redaction of personal identifiable information only. 
 
 
 
. 
 
 
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 1 of 67
Protocol
Trial ID:NN2211-4232
LIRA-PRIME: Efficacy in controlling glycaemia with Victoza®(liraglutide) as 
add-on to metformin vs. OADs as add-on to metformin after up to 104 weeks of 
treatment in subjects with type 2 diabetes inadequately controlled with 
metformin monotherapy and treated in a primary care setting
A 104-week randomised, phase 4, two-arm, open-label, active-controlled, multicentre, 
multinational, parallel-group trial
Trial phase: 4
Protocol originators
Clinical trial management
Novo Nordisk A/S
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849120] of abbreviations.......................................................................................................... ...............................6
1 Summary....................................................................................................................... .............................7
2 Flow chart .................................................................................................................... ............................10
3 Background information and rationale for the trial............................................................................ 13
3.1 Background information...................................................................................................... ........13
3.2 Rationale for the trial ..................................................................................................... ..............13
4 Objectives and endpoints...................................................................................................... ..................14
4.1 Objectives .................................................................................................................. ..................14
4.2 Endpoints ................................................................................................................... ..................14
4.2.1 Primary endpoint........................................................................................................14
4.2.2 Secondary endpoints..................................................................................................15
[IP_ADDRESS] Supportive seconda ry endpoints..........................................................[ADDRESS_849121] replacement......................................................................................................... ............20
6.6 Rationale for trial population.............................................................................................. .........20
6.7 Pre-trial HbA 1c.............................................................................................................................21
7 Milestones.................................................................................................................... .............................21
8 Methods and a ssessments ....................................................................................................... ................21
8.1 Visit procedures ............................................................................................................ ...............21
8.1.1 Informed consent .......................................................................................................218.1.2 Investigator site logs ..................................................................................................22
8.1.3 Screening ................................................................................................................. ..22
8.1.4 Randomisation ...........................................................................................................22
8.1.5 Withdrawals............................................................................................................... 22
8.1.6 Site visits............................................................................................................... .....22
8.1.7 Visits attended fasting................................................................................................23CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849122] related information................................................................................................. .........23
8.2.1 Concomitant illness a nd medical history ...................................................................23
8.2.2 Concomitant medication............................................................................................238.2.3 Demography...............................................................................................................2 4
8.2.4 Diabetes details.......................................................................................................... 24
8.2.5 Smoking status...........................................................................................................2 4
8.3 Assessments................................................................................................................. ................24
8.3.1 Body measurements...................................................................................................248.3.2 Vital signs ............................................................................................................... ...24
8.3.3 Hypoglycaemic epi[INVESTIGATOR_1841] ...........................................................................................25
8.3.4 Self-measured blood glucose (SMBG) ......................................................................[ADDRESS_849123] compliance.......................................................................................................... ............28
9 Trial supplies ................................................................................................................ ...........................29
9.1 Trial products.............................................................................................................. .................29
9.2 Labelling ................................................................................................................... ...................29
9.3 Storage ..................................................................................................................... ....................30
9.4 Drug accountability and destruction ......................................................................................... ...30
9.5 Auxiliary supplies.......................................................................................................... ..............31
10 Interactive web re sponse system.............................................................................................. ..............31
11 Randomisation procedure ...................................................................................................... ................32
12 Adverse events, technical comp laints and pregnancies .......................................................................32
12.1 Definitions ................................................................................................................ ...................32
12.2 Reporting of adverse events................................................................................................ .........36
12.3 Follow-up of adverse events ................................................................................................ ........38
12.4 Technical complaints and tec hnical complaint samples ..............................................................40
12.4.1 Reporting of technical complaints .............................................................................40
12.4.2 Collection, storage and shipment of technical complaint samples ............................41
12.5 Pregnancies ................................................................................................................ ..................41
12.5.1 Pregnancies in  female subjects ..................................................................................41
12.5.2 Pregnancies in female partners of male subjects (Applicable to US only)................43
12.6 Precautions and/or overdose ................................................................................................ ........44
12.7 Committees related to safety............................................................................................... .........44
12.7.1 Novo Nordisk sa fety committee ................................................................................44
13 Case report forms............................................................................................................ ........................44
13.1 Corrections to cas e report forms........................................................................................... .......45
13.2 Case report form flow...................................................................................................... ............45
14 Monitoring procedures ........................................................................................................ ...................45
15 Data management.............................................................................................................. ......................46
16 Computerised systems......................................................................................................... ....................46
17 Statistical considerations ................................................................................................... .....................47CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 4 of 67
17.1 Sample size calculation.................................................................................................... ............47
17.2 Definition of analysis sets................................................................................................ ............48
17.3 Primary endpoint........................................................................................................... ...............49
17.4 Secondary endpoints........................................................................................................ ............49
17.4.1 Supportive seconda ry endpoints ................................................................................49
[IP_ADDRESS] Efficacy endpoints...............................................................................49
[IP_ADDRESS] Safety endpoints ..................................................................................[ADDRESS_849124] during trial ........................................................................................ .......57
18.5 Premature termination of the trial and/or trial site....................................................................... 57
19 Protocol compliance.......................................................................................................... ......................58
20 Audits and inspections ....................................................................................................... .....................58
21 Critical documents ........................................................................................................... .......................59
22 Responsibilities ............................................................................................................. ...........................60
23 Reports and publications..................................................................................................... ...................61
23.1 Communication of results................................................................................................... .........61
23.1.1 Authorship ............................................................................................................... ..62
23.1.2 Site-specific publication(s) by [CONTACT_1697](s) ...........................................................62
23.2 Investigator access to data and review of results .........................................................................6 3
24 Retention of clinical trial documentation.................................................................................... ..........63
24.1 Retention of clinical trial documentation.................................................................................. ...63
25 Institutional Review Boards/Independent Ethics Committees and regulatory authorities..............64
26 Indemnity statement .......................................................................................................... .....................64
27 References ................................................................................................................... .............................66
Attachment I – Global list of key staff and relevant departments and suppliersCONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 5 of 67
Table of Figures and Tables
Page
Figure 5–1 Schematic overview  of the tr ial design............................................................................... ....16
Figure 12–1 Initial reporting of AEs............................................................................................ ..............38
Table 17–1 Sample size calculations for different scenarios – total number of randomised subjects......48
Figure 17–1 Novo Nordisk classification of hypoglycaemia.....................................................................54
Figure 17–2 ADA classification of hypoglycaemia................................................................................. ...55CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849125] visitGCP Good Clinical PracticeGLP-1 glucagon-like peptide-1HbA
1c glycosylated haemoglobin
IEC independent ethics committeeIRB institutional review boardIWRS interactive web response systemMESI medical event of special interestOAD oral antidiabetic drugSAE serious adverse eventSGLT-2 Sodium/glucose cotransporter 2SDV source data verificationSmPC summary of product characteristicsS[LOCATION_003]R suspected unexpected serious adverse reactionT2D type 2 diabetesUTN Universal Trial NumberCONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 7 of 67
1 Summary
Objectives and endpoints:
Primary objective:
To compare the efficacy in controlling glycaemia with Victoza®(liraglutide) as add-on to 
metformin vs. oral antidiabetic drugs (OADs) as add-on to metformin after up to 104 weeks of 
treatment in subjects with type 2 diabetes (T2D) treated in primary care, inadequately controlled 
with metformin monotherapy.
Secondary objective:
To compare efficacy and safety of Victoza®as add-on to metformin vs. OADs as add-on
to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes (T2D) treated in
primary care, inadequately controlled with metformin monotherapy.
Primary endpoint:
Time to inadequate glycaemic control defined as HbA 1c> 7.0% (53 mmol/mol) at two scheduled 
consecutive visits after the first 26 weeks of treatment and up to 104 weeks.
Key supportive secondary endpoints:
!Number of subjects who at 104 weeks or at premature treatment discontinuation achieve 
(Yes/No):
oHbA 1c≤ 6.5% (48 mmol/mol) 
oHbA 1c≤7.0% (53 mmol/mol) without weight gain
!Change from baseline at 104 weeks or at premature treatment discontinuation in:
oFasting plasma glucose (FPG)
oBody weight
Trial design:
This is a 104-week randomised, two-arm, open-label, active-controlled, multicentre, multi-national, 
parallel-group, phase 4 trial.
Trial population:
It is planned to randomise 1994 subjects.
Key inclusion criteria:
!Male or female ≥ 18 years of age at the time of signing informed consent.
!Subjects diagnosed (clinically) with type 2 diabetes ≥90 days prior to the screening visit.
!Stable daily dose of metformin as monotherapy ≥ 1500 mg or maximum tolerated dose 
within 60 days prior to the screening visit.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 8 of 67
!HbA 1c7.5-9.0% (59-75 mmol/mol) (both inclusive) and measured within the last 90 days 
prior to the screening visit.
Key exclusion criteria:
!Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing 
potential and not using adequate contraceptive methods (adequate contraceptive measures as required by [CONTACT_17993]).
!Receipt of any investigational medicinal product within 30 days before the screening visit.
!Treatment with any medication for the indication of diabetes other than metformin in a 
period of 60 days before the screening visit. An exception is short-term treatment ( ≤7 days 
in total) with insulin in connection with intercurrent illness.
!Any disorder, which in the investigator’s opi[INVESTIGATOR_36174]’s safety or 
compliance with the protocol.
Definition of primary care:
This trial will be conducted in a primary care environment which is defined as a non-
endocrinologist, non-diabetologist clinic/practice/surgery or equivalent that provides continuing 
care to persons with any undiagnosed sign, symptom or health concern not limited by [CONTACT_635611] (biological, behavioural or social), organ system or diagnosis. The primary care practice may 
be the patient’s first point of contact [CONTACT_85595]. 
The doctors/physicians that work in primary care are often referred to as general practitioners 
(GPs), primary care doctors/physicians and family doctors/physicians. The primary care practice 
may include a team of physicians and other health care professionals.
The definition of primary care is adapted from the definition used by [CONTACT_635612] (AAFP)
1. 
Assessments:
!HbA 1c
!Fasting plasma glucose
!Body weight
!Hypoglycaemic epi[INVESTIGATOR_36177]:
Victoza®:
!Victoza®(liraglutide 3.0 mL;6.0 mg/mL)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 9 of 67
Oral antidiabetic drugs ( OADs):
!Alpha-glucosidase inhibitors
!DPP-4 inhibitors
!Meglitinides
!SGLT-2 inhibitors
!Sulphonylureas  
!ThiazolidinedionesCONFIDENTIAL
Protocol UTN: U1111-1170-7035 Date: 04 September 2015 Status: Final Novo Nordisk
Trial ID: NN2211-[ADDRESS_849126] no.: 2015-002417-29 Version: 1.0 Page: 10 of 67
2 Flow chart
Trial Periods Screening1 Random
isation TreatmentEnd of 
treatmentFollow up
Visit type S S P/S2S S S S S S S S S P
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13
Timing of visit , Weeks Up to -2 0 2 4 16 26 38 52 65 78 91 104 105
Visit window, Days ±7 ±4 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±4 +4
Informed consent x
In/exclusion criteria x
Randomisation x
IWRS session x x
Withdrawal criteria3x x x x x x x x x x
Medical history /Concomitant 
illnessx
Concomitant medication x x x x x x x x x x x x x
Demography x
Diagnosis of diabetes x
Diabetes complications x x x
Diabetes treatment history x
Smoking status x
Pregnancy urine test x (x) (x) (x) (x) (x) (x) (x) (x) (x) (x) x
Handout ID card x
Height x
Body weight x x x x x x x x x x
Blood sampling x x xxxxxxx x
- Fasting plasma glucose x x x x x
-H b A 1c x xxxxxxx x
- Lipi[INVESTIGATOR_805] x x x
- Biochemistry x x x
- Haematology x x x
Attend visit fasting x x x x x
Protocol UTN: U1111-1170-7035 Date: 04 September 2015 Status: Final Novo Nordisk
Trial ID: NN2211-[ADDRESS_849127] no.: 2015-002417-29 Version: 1.0 Page: 11 of 67
Trial Periods Screening1 Random
isation TreatmentEnd of 
treatmentFollow up
Visit type S S P/S2S S S S S S S S S P
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13
Timing of visit , Weeks Up to -2 0 2 4 16 26 38 52 65 78 91 104 105
Visit window, Days ±7 ±4 ±10 ±10 ±10 ±10 ±10 ±10 ±10 ±4 +[ADDRESS_849128] handlingx (x)4(x)4(x)4(x)4(x)4(x)4(x)4(x)4(x)4
Drug accountability x x x x x x x x x
Adverse events x x x x x x x x x x x x
Hypoglycaemic epi[INVESTIGATOR_1841] x x x x x x x x x x x x
Technical complaints x x x x x x x x x x
End of treatment x
End of trial x
Sign off Casebook x
Abbreviations: IWRS: Interactive web response system; P/S: Phone contact/Site visit; S: Site visit; P: Phone contact
1Procedures and assessments relating to visit 1 may be conducted at visit 2 prior to randomisation. Trial related procedures (inclu ding 
requesting the subject to be fasting) are not allowed before signing of informed consent
2Visit [ADDRESS_849129] or a site visit at the discretion of the investigator.
3Subjects withdrawing from the trial should attend end of treatment visit as soon as possible.
Protocol UTN: U1111-1170-7035 Date: 04 September 2015 Status: Final Novo Nordisk
Trial ID: NN2211-[ADDRESS_849130] no.: 2015-002417-29 Version: 1.0 Page: [ADDRESS_849131] handling to be given at the discretion of the investigator.
5Diaries should be reviewed at every visit. Relevant data should be reported into the eCRF.
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849132] of 
the clinical trial at a trial site.
Information about Victoza® (liraglutide) (hereafter referred to as Victoza®) and oral antidiabetic 
drugs (OAD’s) used as comparators is available in the approved local label documents.
The HbA 1c lowering effect of Victoza®in subjects with type 2 diabetes (T2D) is well established. 
The completed phase 3 and phase 4 trials with Victoza®have tested Victoza®in most treatment 
scenarios used for patients with T2D including combination with metformin4. In all these treatment 
scenarios the efficacy of Victoza®was demonstrated and there were no major safety concerns. 
Furthermore, Victoza®has been shown to be safe and efficacious in subjects with moderate renal 
impairment5.
For an assessment of benefits and risks of the trial, see section 18.1.
3.[ADDRESS_849133] antidiabetic drug6. Thus, the durability of the glycaemic 
control of the antidiabetic drugs added when metformin monotherapy no longer provides adequate glycaemic control is important. GLP-1 receptor agonists (RAs) are recommended as a potential 
second line treatment in the American Diabetes Association (ADA) and the European Association 
for the study of Diabetes (EASD) position statement
7. However, the durability of the glucose-
lowering effect of GLP-[ADDRESS_849134] suggested that GLP-1 may increase β-cell mass and function in animal models8,9. 
Further, GLP-1 RAs may improve β-cell function and growth in human subjects. One trial reported 
that in patients with T2D Victoza®provided robust enhancement of β-cell function that was 
sustained over 48 weeks10. Therefore, early introduction of Victoza®may promote durability of 
glycaemic control.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849135] clinical 
trials are conducted in secondary care units. This may make the generalisability of the trial results -
ie. whether the results can be reasonably applied to routine primary care practice -  challenging11,12.  
The objective of this trial is to compare the efficacy in controlling glycaemia with Victoza®as add-
on to metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects 
with type 2 diabetes treated in primary care, inadequately controlled with metformin monotherapy.
4 Objectives and endpoints
4.1 Objectives
Primary objective:
To compare the efficacy in controlling glycaemia with Victoza®(liraglutide) as add-on to 
metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects with 
T2D treated in primary care, inadequately controlled with metformin monotherapy.
Secondary objective:
To compare efficacy and safety of Victoza®as add-on to metformin vs. OADs as add-on
to metformin after up to 104 weeks of treatment in subjects with type 2 diabetes (T2D) treated in
primary care, inadequately controlled with metformin monotherapy.
4.2 Endpoints
4.2.1 Primary endpoint
Time to inadequate glycaemic control defined as HbA 1c> 7.0% (53 mmol/mol) at two scheduled 
consecutive visits after the first 26 weeks of treatment and up to 104 weeks.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 15 of 67
4.2.2 Secondary endpoints
[IP_ADDRESS] Supportive secondary endpoints
!Time to premature treatment discontinuation (for any reason including inadequate glycaemic 
control)
!Change from baseline in HbA 1cat 104 weeks or at premature treatment discontinuation
!Number of subjects who at 104 weeks or at premature treatment discontinuation achieve 
(Yes/No):
oHbA 1c≤ 6.5% (48 mmol/mol) *
oHbA 1c≤7.0% (53 mmol/mol) without weight gain *
oHbA 1c≤7.0%  (53 mmol/mol) without treatme nt emergent severe hypoglycaemic 
epi[INVESTIGATOR_635595] 1c≤7.0% (53 mmol/mol) without weight gain and no treatment emergent severe 
hypoglycaemic epi[INVESTIGATOR_635596]
!Change from baseline at 104 weeks or at premature treatment discontinuation will be 
evaluated for:
oFasting plasma glucose (FPG) *
oBody weight *
oBMI
oSystolic and diastolic blood pressure
!Number of severe hypoglycaemic epi[INVESTIGATOR_1841]
!Number of severe or blood glucose confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_1841]
!Number of documented symptomatic hypoglycaemic epi[INVESTIGATOR_1841] (ADA)
!Number of serious adverse events (SAEs)
!Number of AEs leading to permanent discontinuation of trial product
!Change from baseline at 104 weeks or at premature treatment discontinuation will be 
evaluated for:
oLipi[INVESTIGATOR_635597]
* Key supportive secondary endpoint prospectively selected for disclosure (e.g. clinicaltrials.gov 
and EudraCT)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 16 of 67
5 Trial design
5.1 Type of trial
This is a 104-week randomised, two-arm, open-label, active-controlled, multicentre, multi-national, 
parallel-group, phase 4 trial.
The trial will be conducted in the primary care setting. Please refer to definition in section 5.2
Subjects’ eligibility is based on the subjects’ medical history including HbA 1c, measured up to 90 
days before screening. 
Subjects will be randomised to one of two treatment arms: Victoza®or OAD. The OAD (see list 
below in section 5.4) will be chosen at the discretion of the investigator. Trial product will be 
prescribed by [CONTACT_635613] (see section 9).
The maximum trial duration for the individual subjects will be up to approximately 107 weeks. The 
trial includes an up to 2-week screening period, followed by [CONTACT_79963] 104-week randomised 
treatment period and a 1-week follow up period after end of treatment. Please see Figure 5–1 for a 
schematic overview of the trial.
Figure 5–[ADDRESS_849136] clinic/practice/surgery or equivalent that provides continuing 
care to persons with any undiagnosed sign, symptom or health concern not limited by [CONTACT_635614]: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 17 of 67
origin (biological, behavioural or social), organ system or diagnosis. The primary care practice may 
be the patient’s first point of contact [CONTACT_85595]. 
The doctors/physicians that work in primary care are often referred to as general practitioners 
(GPs), primary care doctors/physicians and family doctors/physicians. The primary care practice 
may include a team of physicians and other health care professionals.
The definition of primary care is adapted from the definition used by [CONTACT_635612] (AAFP)1
5.3 Rationale for trial design
A randomised, parallel-group trial design with two treatment arms has been chosen to avoid bias. A 
104-week duration has been chosen as this was deemed appropriate for assessing time to inadequate 
glycaemic control. Due to the duration of the trial and the prescription of trial drug by [CONTACT_635615]-label design has been chosen as a double-dummy design was deemed 
unfeasible.
5.4 Treatment of subjects
After randomisation, subjects in the Victoza®arm will initiate treatment with 0.6 mg/day with 
subsequent dose escalation according to approved local label up to final dose of 1.8 mg/day at the 
discretion of the investigator. A maintenance dose of 1.[ADDRESS_849137]’s HbA 1cis <
7.0% (53 mmol/mol), however, escalation to 1.8 mg should be attempted if the subjects’ HbA 1cis ≥
7% (53 mmol/mol). 
Subjects randomised to the OAD arm will initiate treatment with one OAD selected at the discretion 
of the investigator and, if relevant for the specific OAD, will escalate the dose to the maximum 
approved or maximum tolerated dose according to approved local label at the discretion of the 
investigator. A maintenance dose below the maximum approved or maximum tolerated dose is 
acceptable if the subject’s HbA1c is < 7.0% (53 mmol/mol). However, escalation to the maximum 
approved or maximum tolerated dose should be attempted, at the discretion of the investigator, if 
the subjects’ HbA1c is ≥ 7% (53 mmol/mol). Subjects randomised to the OAD arm must remain on 
the same OAD throughout the trial. 
After randomisation, subjects must remain on the same antidiabetic drugs throughout the trial.Subjects will receive Victoza
®or the OAD treatment for a maximum of 104 weeks.
Victoza®and the OADs will be handled and dispensed by [CONTACT_635616]´s trial participation.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 18 of 67
Subjects can receive the following antidiabetic drugs:
!Victoza®
!Oral antidiabetic drugs: The OADs included in this trial are:
– Alpha-glucosidase inhibitors
– Dipeptidyl peptidase 4 (DPP-4) inhibitors
– Meglitinides
– Sodium/glucose cotransporter 2 (SGLT-2) inhibitors
– Sulphonylureas
– Thiazolidinediones
Victoza®and OADs must be used in accordance with approved local labels at the discretion of the 
investigator. Fixed dose antidiabetic combination products (e.g. metformin plus DPP-4 inhibitor 
combinations) are not allowed in this trial. 
Subjects should start the treatment they are randomised to as soon as possible and preferably no 
later than 5 days after randomisation. 
Background medication: Metformin is considered background medication. The background 
metformin treatment must be maintained at the pre-trial dose and frequency during the entire trial
treatment period unless there is a safety concern. Metformin is not provided or reimbursed by [CONTACT_49753].
5.[ADDRESS_849138]. Novo Nordisk will not provide or reimburse treatment after trial discontinuation.
5.6 Rationale for treatment
Victoza®and OADs will be used according to local approved labels in order to compare the real life 
efficacy in the two treatment arms. The OAD will be chosen at the discretion of the investigator in 
order to compare Victoza®to the OADs most relevant for the individual patient. 
Background metformin has been chosen as this is the recommended first line treatment for type [ADDRESS_849139] be maintained at the pre-trial dose and frequency during the 
trial treatment period in order to be able to compare the efficacy of Victoza®and OADs.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 19 of 67
6 Trial population
6.1 Number of subjects 
Number of subjects planned to be randomised: 1994
Number of subjects expected to complete the trial (defined as treated with trial product for 104 
weeks): [ADDRESS_849140] be answered “yes”. 
1. Informed consent obtained before any trial-related activities. Trial-related activities are any 
procedures that are carried out as part of the trial, including activities to determine suitability for 
the trial. 
2. Male or female ≥ 18 years of age at the time of signing informed consent.
3. Subjects diagnosed (clinically) with type 2 diabetes ≥90 days prior to the screening visit.
4. Stable daily dose of metformin as monotherapy ≥ 1500 mg or maximum tolerated dose within 
60 days prior to the screening visit. 
5. HbA 1c7.5-9.0% (59-75 mmol/mol) (both inclusive) and measured within the last 90 days prior 
to the screening visit.
6. Patients in which Victoza®and OAD treatment are indicated according to approved local label.
6.[ADDRESS_849141] be answered "no".
1. Previous participation in this trial. Participation is defined as signed informed consent.
2. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing 
potential and not using adequate contraceptive methods (adequate contraceptive measures as 
required by [CONTACT_17993]).
3. Receipt of any investigational medicinal product within 30 days before the screening visit.
4. Treatment with any medication for the indication of diabetes other than metformin in a period of 
60 days before the screening visit. An exception is short-term treatment ( ≤7 days in total) with 
insulin in connection with intercurrent illness.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 20 of 67
5. Any disorder, which in the investigator’s opi[INVESTIGATOR_36174]’s safety or 
compliance with the protocol.
6.[ADDRESS_849142]´s request to discontinue must always be 
respected. The subject may be withdrawn from the trial at the discretion of the investigator due to a 
safety concern.
The subject must be withdrawn from the trial if the following applies:
1. Included in the trial in violation of the inclusion and/or exclusion criteria.
2. Pregnancy or intention of becoming pregnant.
3. Participation in another clinical trial throughout the trial
4. Use of any antidiabetic medication during the trial other than background metformin, and 
randomised antidiabetic treatment except short-term insulin ( ≤7 days in total) treatment in 
connection with intercurrent illness.
5. Inadequate glycaemic control defined as HbA 1c> 7.0% (53 mmol/mol) at two scheduled 
consecutive visits after the first [ADDRESS_849143] line treatment of 
T2D recommended by [CONTACT_635617]. 
The inclusion criteria are chosen to include a population of patients with T2D treated with 
metformin monotherapy, who are inadequately controlled and may benefit from treatment with 
Victoza®or an OAD in addition to metformin treatment. Stable pre-trial treatment prevents recent 
dose changes affecting trial endpoints. A minimum of exclusion criteria is chosen in order to reflect a real life setting.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849144] meets inclusion criterion 5, the requirements for documentation 
are:
!The most recent available HbA 1c obtained by a health care professional and documented in
the medical records.
!Only HbA 1cmeasured within the last [ADDRESS_849145] be obtained prior to performing any trial related HbA 1cmeasurement.
7 Milestones
Planned duration of recruitment period: [ADDRESS_849146] Visit.
Recruitment:
All investigators will be notified immediately when the recruitment period ends, after which no 
subjects may be screened.
Trial registration:
Information of the trial will be disclosed at clinicaltrials.gov and novonordisk-trials.com. According 
to the Novo Nordisk Code of Conduct for Clinical Trial Disclosure13, it will also be disclosed 
according to other applicable requirements such as those of the International Committee of Medical 
Journal Editors (ICMJE)14, the Food and Drug Administration Amendment Act (FDAAA)15, 
European Commission Requirements16,17and other relevant recommendations or regulations. If a 
subject requests to be included in the trial via the Novo Nordisk e-mail contact [CONTACT_36283], 
Novo Nordisk may disclose the investigator’s contact [CONTACT_18026]. As a result of increasing 
requirements for transparency, some countries require public disclosure of investigator names and 
their affiliations.
8 Methods and assessments
The following sections describe the assessments and procedures. These are also included in the flow 
chart (see section 2) along with their timing.
8.[ADDRESS_849147] be obtained before any trial related activity; see section 18.2.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849148] address(es) and telephone number(s) of relevant trial site staff. Subjects should be 
instructed to return the card to the investigator at the last trial visit or to destroy the card after the 
last visit. A screening session must be performed in IWRS (see section 10). Each subject will be 
assigned a unique 6-digit subject number which will remain the same throughout the trial.
For screening failures the screening failure form in the electronic case report form (eCRF) must be 
completed with the reason for not continuing in the trial. Serious adverse events from screening 
failures must be transcribed by [CONTACT_215546]. Follow-up of serious adverse events 
(SAEs) must be carried out according to section 12.
A screening failure session must be made in the IWRS. The case book must be signed. 
8.1.[ADDRESS_849149] be performed in IWRS (see section 10).
8.1.[ADDRESS_849150] (visit 13) should be completed 
approximately [ADDRESS_849151] is not obliged to give his/her reason(s) for withdrawing from a trial, the 
investigator must make a reasonable effort to ascertain the reason(s), while fully respecting the 
subject’s rights. Where the reasons are obtained, the primary reason for not completing the trial 
must be specified on the end-of-trial form in the eCRF.
8.1.[ADDRESS_849152] an appointment with the subjects for the site visits. 
If a site visit is missed and it is not possible to re-schedule, the investigator should ensure that 
relevant information is collected for example over the phone.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849153].
Procedures and assessments performed at visit 1 and/or 2 are considered screening procedures. The 
results of these procedures should be considered pre-existing conditions and should be reported as 
medical history or concomitant illness
Relevant concomitant illness/medical history related to diabetes should be transcribed to the eCRF. 
The information collected for concomitant illness/medical history should include diagnosis, date of 
onset and date of resolution or continuation, as applicable.
Any relevant change to a concomitant illness should be recorded during the trial. A clinically 
significant worsening of a concomitant illness must be reported as an AE, if the event meets the 
SAE criteria or is an AE leading to permanent treatment discontinuation according to section 12.2.
8.2.[ADDRESS_849154] be recorded at each visit as they occur. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849155]’s eligibility to 
continue in the trial, the monitor must be informed.
8.2.[ADDRESS_849156] be recorded:
!Date of birth
!Sex
!Race
!Ethnicity
Investigators must document whether females are of childbearing potential.
8.2.4 Diabetes details
Details regarding diagnosis of diabetes (diabetes type and date of diagnosis), diabetes complications 
and diabetes treatment history (dose, start and stop date of current diabetes treatment) must be 
recorded in the eCRF at visit 1.
8.2.[ADDRESS_849157] is sitting.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 25 of 67
8.3.3 Hypoglycaemic epi[INVESTIGATOR_635598] a hypogl ycaemic epi[INVESTIGATOR_36190]. 
All plasma glucose values:
!≤ 3.9 mmol/L (70 mg/dL) or 
!> 3.9 mmol/L (70 mg/dL) when they occur in conjunction with hypoglycaemic symptoms
should be recorded by [CONTACT_423]. These must  be transcribed into the eCRF (hypoglycaemic 
epi[INVESTIGATOR_215510]) throughout the trial from visit [ADDRESS_849158] should include the following information:
!Date and time of hypoglycaemic epi[INVESTIGATOR_1865]
!The plasma glucose level before treating the epi[INVESTIGATOR_1865] (if available) 
!Whether the epi[INVESTIGATOR_36202] 
!Whether the subject was able to treat him/herself
!Date and time of last antidiabetic treatment administration prior to epi[INVESTIGATOR_1865] 
!Type and dose of last antidiabetic treatment administration prior to epi[INVESTIGATOR_1865] 
!Date and time of last main meal prior to epi[INVESTIGATOR_1865]
!Whether the subject was asleep when the epi[INVESTIGATOR_36206]
– If yes, whether the symptoms of the epi[INVESTIGATOR_513399]: "Was subject able to treat him/herself?" must be answered "No" for an 
epi[INVESTIGATOR_36208], glucagon, or 
take other corrective actions. Plasma glucose concentrations may not be available during an event, 
but neurological recovery following the return of plasma glucose to normal is considered sufficient 
evidence that the event was induced by a low plasma glucose concentration10. 
Oral carbohydrates should not be given if the subject is unconscious.
If the question "Was subject able to treat him/herself?" is answered "No", the following information 
should be recorded:
!Who assisted in the treatment of the hypoglycaemic epi[INVESTIGATOR_1865] (i.e. family/friend/co-worker or 
similar, paramedic, doctor or other, please specify)
!Where the treatment was administered (i.e. at home/at friends/at work or similar, in an 
ambulance, emergency room/hospi[INVESTIGATOR_36209], please specify)
!Type of treatment provided by [CONTACT_215559] (i.e. oral carbohydrates, glucagon, IV glucose or 
other, please specify)
!Were symptoms alleviated after administration of treatment?CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 26 of 67
!Factors contributing to the epi[INVESTIGATOR_1865] (i.e. physical activity, missed meal, diet changed, 
medication error (i.e. overdose, mix-up between products), other factors not listed, please 
specify or none)
!Did the subject experience seizure?
!Was the subject unconscious/comatose?
!Did the subject experience any of the following symptoms? 
– Autonomic: sweating, trembling, hunger or palpi[INVESTIGATOR_814]
– Neuroglycopenic: confusion, drowsiness, speech difficulty, visual disturbances, odd 
behaviour, impaired balance or incoordination
– General malaise: headache or malaise
!Did the subject experience other symptoms? Please specify
!Description of the epi[INVESTIGATOR_1865], if applicable 
A hypoglycaemic epi[INVESTIGATOR_635599]. If the 
hypoglycaemic epi[INVESTIGATOR_135520] a safety information 
form must also be filled in, see section 12.
8.3.4 Self-measured blood glucose (SMBG)
At Visit 2, subjects will be provided with a blood glucose meter including lancets, plasma-
calibrated test strips and control solutions as well as instructions for use. The subjects will be 
instructed on how to use the device, the instruction will be repeated as necessary during the trial. 
The blood glucose meters use test strips calibrated to plasma values. Therefore, all measurements 
performed with capi[INVESTIGATOR_36191], 
which will be shown on the display. 
Subjects should be instructed on how to record the results of the SMBGs in the diaries and to only 
record them in the diaries in case of hypoglycaemic epis odes. All relevant data from the diary must 
be transcribed into the eCRF during or following the contact. If obtained via phone and a 
discrepancy is later detected, the values in the eCRF should be corrected.
8.3.[ADDRESS_849159] be provided with diaries at the specified visits (section 2). During the trial subjects 
should use the diary for the below: 
!to record their blood glucose values in case of hypoglycaemic epi[INVESTIGATOR_1841]
!to record any new concomitant medication during the trial
!to record dose changes to metformin, Victoza®or OAD treatment (date of change, new trial 
product dose and reason for dose change)
!to record any adverse events experienced by [CONTACT_635618]: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 27 of 67
In addition, subjects should be instructed to note the date, time and blood glucose value (if 
available) if they experience a hypoglycaemic epi[INVESTIGATOR_635600]. 
Subjects are requested to bring the diary to each visit. The diary must be collected and retained at 
the site as source data, and the subject will receive a new diary.
The investigator must review the subject diaries to ensure the relevant entries are transcribed to the 
eCRF. If clarification of entries or discrepancies is needed, the subject must be questioned and a
conclusion made in the medical record. Care must be taken not to bias the subject. To verify that the 
data have been reviewed, the investigator must sign and date the diaries or ensure the review is
documented in the subject’s medical record.
8.3.[ADDRESS_849160] kits (urine-sticks). For female subjects who are of 
child-bearing potential (at the discretion of the investigator), a pregnancy test must be performed on 
site at screening. For females of child-bearing potential pregnancy test should be repeated at end of
treatment and at any time during the trial, if a menstrual period is missed or pregnancy is suspected 
or as required by [CONTACT_427]. The date and result of the pregnancy tests must be recorded in 
the subject’s medical record and the results must be transcribed to the eCRF.
8.[ADDRESS_849161]’s medical record. The laboratory report and evaluation are retained at the investigator’s site 
as source documentation.
For laboratory report values outside the reference range, the investigator must specify whether the 
value is or is not clinically significant. 
Laboratory materials, flow charts and a laboratory manual will be provided to each site. The 
documents will include instruction on handling, transportation and storage of the blood samples, as 
well as contact [CONTACT_635619].
The laboratory analyses are:Glucose metabolism
!Fasting plasma glucose
!HbA
1cCONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 28 of 67
Lipi[INVESTIGATOR_805]
!Cholesterol
!High density lipoprotein (HDL) cholesterol
!Low density lipoprotein (LDL) cholesterol
!Triglycerides
Biochemistry
!Creatinine
!eGFR (calculated value)
!Alanine aminotransferase (ALT)
!Aspartate Aminotransferase (AST)
!Potassium
!Bilirubin
!Lipase
!Amylase
Haematology
!Haemoglobin
The laboratory provides results to the trial sites in the units preferred by [CONTACT_135545].
The laboratory equipment may provide analyses not requested in the protocol but produced 
automatically in connection with the requested analyses according to specifications in the laboratory 
standard operating procedures. Such data will not be transferred to the trial database, but abnormal 
values will be reported to the investigator. The investigator must review all laboratory results for 
concomitant illnesses and adverse events and report these according to this protocol see section 
12.2. 
8.[ADDRESS_849162] of the importance of following the instructions given including 
taking the trial products as prescribed.
Treatment compliance: Treatment compliance will not be measured as the trial is designed to 
reflect everyday practice.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849163] not be used by [CONTACT_635620]. 
9.1 Trial products
Trial products used in this trial are:
Victoza®:
!Victoza®(liraglutide 3.0 mL;6.0 mg/mL)
Oral antidiabetic drugs ( OADs):
!Alpha-glucosidase inhibitors
!DPP-4 inhibitors
!Meglitinides
!SGLT-2 inhibitors
!Sulfonylureas  
!Thiazolidinediones
Trial products will be commercial products dispensed from pharmacies or similar means in 
accordance with local regulation/practice and hence trial product will not be supplied by [CONTACT_49753]. Dispensing of trial products will be based on Investigator prescriptions. The prescription 
must be in accordance with subject randomisation to either Victoza®or OAD treatment arm. Trial 
products will be reimbursed by [CONTACT_635621]´s trial participation.
It is the responsibility of the investigator that the patient is instructed in the use of trial drug during 
the trial and the expected adverse events.
Further information for trial products is available in approved local labels and package inserts.
Metformin is background treatment in this trial hence not trial product and will neither be supplied 
nor reimbursed by [CONTACT_3454].
9.[ADDRESS_849164] a dispensing 
label with particulars added to the original container without obscuring the original labelling:
For Serbia the following particulars will be added:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 30 of 67
!Name [CONTACT_119019]
!Trial ID 
!Subject number (this allows identification of the trial site, investigator and trial subject)
!For clinical trial use only
For Russia the following particulars will be added:
!Name [CONTACT_119019]
!Trial ID
!Subject number (this allows identification of the trial site, investigator and trial subject)
!Investigator information
!For clinical trial 
!Dispensing unit number (allocated by [CONTACT_1714])
For Turkey the following particulars will be added:
!Name [CONTACT_119019]
!Trial ID
!Subject number (this allows identification of the trial site, investigator and trial subject)
!Site number
!Investigator information
!For clinical trial use only
!Keep out of reach and sight of the children
Adding the dispensing label will be carried out by [CONTACT_230996]/trained specialist at a 
pharmacy or similar and documented.  
Further information will be available in a country specific document describing the local process.
Applicable for Canada, India, Latvia, Lebanon and US
Commercially supplied trial products will not have any additional labelling.   
9.3 Storage 
Trial products are supplied commercially and hence will not be stored at site. 
9.4 Drug accountability and destruction
Drug accountability is the responsibility of the investigator.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849165] by [CONTACT_1697]. At each 
visit (except for visit number 3) the Investigator will prescribe trial product and at the next visit the 
subject will return to the site used, partly used and not used trial products dispensed from the 
pharmacy. At the site it will be documented what was prescribed and what the subject returned to 
the investigator at the next visit. 
Through this procedure the investigator can verify that correct trial product has been dispensed. 
Applicable for Canada, India, Latvia, Lebanon, Russia, Serbia and Turkey
Trial product (used/partly used or unused including empty packaging material) returned to the site 
can be stored without temperature monitoring. 
Destruction of trial products must be documented.
Applicable for US 
No requirement with regard to documentation of destruction of trial product
9.5 Auxiliary supplies
Auxiliary supplies to the subjects are:
!Blood glucose meters including lancets, plasma-calibrated test strips and control solutions. 
This will be provided by [CONTACT_3454]. User manual will be provided along with the blood 
glucose meter.
For subjects randomised to Victoza®, needles for pre-filled Victoza®pens will be supplied to 
subjects from pharmacies or similar means along with Victoza®and will be reimbursed by [CONTACT_49753]
[ADDRESS_849166] be restricted to and controlled by [CONTACT_36301]. 
IWRS is used for:
!Screening
!Screening failure
!Randomisation
IWRS user manuals will be provided to each trial site.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849167] be used for randomisation. Only eligible subjects are allowed to be randomised.
12 Adverse events, technical complaints and pregnancies
12.1 Definitions
Adverse event 
An adverse event (AE) is any untoward medical occurrence in a subject administered a product, and 
which does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory 
finding), symptom or disease temporally associated with the use of a product, whether or not 
considered related to the product. 
An AE includes:
!A clinically significant worsening of a concomitant illness.
!A clinical laboratory adverse event (CLAE): a clinical laboratory abnormality which is 
clinically significant, i.e. an abnormality that suggests a disease and/or organ toxicity and is 
of a severity that requires active management. Active management includes active treatment 
or further investigations, for example change of medicine dose or more frequent follow-up 
due to the abnormality.
The following should notbe reported as AEs:
!Pre-existing conditions, including those found as a result of screening procedures (pre-
existing conditions should be reported as medical history or concomitant illness).
!Pre-planned procedures unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent.
!Non-serious hypoglycaemia is an AE, but is reported on a hypoglycaemic epi[INVESTIGATOR_135524], see section 8.3.3 .
The following three definitions are used when assessing an AE:
!Severity 
–Mild - no or transient symptoms, no interference with the subject's daily activities.
–Moderate - marked symptoms, moderate interference with the subject's daily activities.
–Severe - considerable interference with the subject's daily activities; unacceptable.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 33 of 67
!Causality 
Relationship between an AE and the relevant trial product(s): 
–Probable - Good reason and sufficient documentation to assume a causal relationship.
–Possible - A causal relationship is conceivable and cannot be dismissed.
–Unlikely - The event is most likely related to aetiology other than the trial product.
!Final outcome
–Recovered/resolved - The subject has fully recovered, or by [CONTACT_36303]-related activity after the 
subject signed the informed consent.
–Recovering/resolving - The condition is improving and the subject is expected to recover 
from the event. This term is only applicable if the subject has completed the trial or has died 
from another AE.
–Recovered/resolved with sequelae - The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequelae meets an 
SAE criterion, the AE must be reported as an SAE.
–Not recovered/not resolved - The condition of the subject has not improved and the 
symptoms are unchanged, or the outcome is not known.
–Fatal - This term is only applicable if the subject died from a condition related to the 
reported AE. Outcomes of other reported AEs in a subject before he/she died should be 
assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as an 
SAE.
–Unknown - This term is only applicable if the subject is lost to follow-up.
Serious adverse event
A serious adverse event (SAE) is an experience that at any dose results in any of the following:
!Death.
!A life-threateningaexperience.
!In-patient hospi[INVESTIGATOR_36220].
!A persistent or significant disability or incapacityc.
!A congenital anomaly or birth defect.
!Important medical events that may not result in death, be life threateninga or require 
hospi[INVESTIGATOR_36221] - based on appropriate medical judgement 
- they may jeopardise the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in the definition of SAEd. 
Suspi[INVESTIGATOR_534937]. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 34 of 67
a. The term "life threatening" in the definition of SAE refers to an event in which the subject was 
at risk of death at the time of the event. It does not refer to an event which hypothetically might 
have caused death if it was more severe.
b. The term "hospi[INVESTIGATOR_11956]" is used when a subject: 
– Is admitted to a hospi[INVESTIGATOR_36222]-patient, irrespective of the duration of physical stay, or 
– Stays at the hospi[INVESTIGATOR_36223] [ADDRESS_849168]'s ability to conduct normal life functions (e.g. following the 
event or clinical investigation the subject has significant, persistent or permanent change, 
impairment, damage or disruption in his/her body function or structure, physical activity and/or 
quality of life).
d. For example intensive treatment in an emergency room or at home of allergic bronchospasm, 
blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_11956], or development of drug 
dependency or drug abuse.
Non-serious adverse event
A non-serious AE is any AE which does not fulfil the definition of an SAE. Medical event of special interest
A medical event of special interest (MESI) is an event which, in the evaluation of safety, has a 
special focus. A MESI is an AE (SAE or non-serious AE) which fulfils one or more of the below
defined MESI criteria.
Medication errors concerning trial products:
– Administration of wrong drug. 
– Wrong route of administration, such as intramuscular instead of subcutaneous.
– Administration of an overdose with the intention to cause harm (e.g. suicide attempt).– Accidental administration of a lower or higher dose than intended, however the 
administered dose must deviate from the intended dose to an extent where clinical 
consequences for the trial subject were likely to happen as judged by [CONTACT_093], 
although they did not necessarily occur.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849169] 
(medicine or device) defects. The technical complaint may be associated with an AE, but does not 
concern the AE itself.
Examples of technical complaints:
!The physical or chemical appearance of trial products (e.g. discoloration, particles or 
contamination)
!The packaging material (e.g. leakage, cracks, rubber membrane issues or errors in labelling 
text)
!Problems related to devices (e.g. to the injection mechanism, dose setting mechanism, push 
button or interface between the pen and the needle)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 36 of 67
12.2 Reporting of adverse events
All events meeting the definition of an SAE (see section 12.1), MESI (see section 12.1), AEs 
leading to permanent discontinuation of trial product and pregnancies (see section 12.5) must be 
collected and reported. This includes events from first trial related activity after the subject has 
signed the informed consent until the end of trial (visit 13). The events must be recorded in the 
applicable eCRF forms in a timely manner, see timelines below and Figure 12–[ADDRESS_849170] be asked about AEs, for example by
[CONTACT_7939]: “Have you experienced any problems since the last contact?” AEs are either observed by 
[CONTACT_98138].
The investigator will evaluate the need for reporting of AEs. The investigator must report the 
following AEs in the eCRF:
!All SAEs
!AEs leading to permanent discontinuation of investigational product
!MESIs
The investigator should report the diagnosis, if available. If no diagnosis is available, the 
investigator should record each sign as individual AEs using separate AE forms. The investigator 
must evaluate the severity and causality for each event.
For SAEs that could have resulted from hypoglycaemia (for example sudden death, seizure, trauma, 
fractures, fall, motor vehicle accident etc), the narrative should include information whether 
hypoglycaemia could have contributed to these events.
!The investigator must enter the AE in the eCRF and tick the seriousness box within 24 hours of 
obtaining knowledge of the SAE
!The safety information form must be completed within [ADDRESS_849171] details (fax, telephone, e-mail and address) are provided to each site.
All SAEs, MESIs and AEs leading to permanent treatment discontinuation observed either by [CONTACT_635622], must be reported by [CONTACT_237215]. Novo Nordisk 
assessment of expectedness is performed according to the following reference documents: 
!Company core data sheet (CCDS), Victoza®, 6.0 mg/mL, version 17.0 or any updates 
thereto
!Non Novo Nordisk A/S marketed products: European summary of product characteristics or 
other relevant labelling, current version or any updates thereto. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849172] specific 
information related to the individual MESI. The AE form for a non-serious AE not fulfilling the 
MESI criteria should be signed when the event is resolved or at the end of the trial.
Timelines for initial reporting of AEs:
The investigator must complete the following forms in the eCRF within the specified timelines:
!SAEs : The AE form within 24 hours and the safety information form within 5 calendar
days of the investigator's first knowledge of the SAE. Both forms must be signed within 7 
calendar days from the date the information was entered in the eCRF. 
!SAEs fulfilling the MESI criteria: In addition to above, the medication error form within 
14 calendar days of the investigator's first knowledge of the AE. 
!Non-serious AE fulfilling the MESI criteria: The AE form, safety information form and 
medication error form within 14 calendar days of the investigator's first knowledge of the 
event.
If the eCRF is unavailable, the concerned AE information must be reported on paper forms and sent 
to Novo Nordisk by [CONTACT_6791], e-mail or courier within the same timelines as stated above. When the 
eCRF becomes available again, the investigator must enter the information on the appropriate forms 
in the eCRF.
Contact [CONTACT_8972] (fax, telephone, e-mail and address) are provided in the investigator trial master file.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 38 of 67
An AE is 
observed and 
reported It is an SAEcomplete:
!AE form ≤ 24 hours
!SIF ≤ 5 calendars days
It is a non-serious AE
complete:
!AE formFulfilling 
seriousness 
criteria?
MESI 
(medication 
error)?MESI 
(medication 
error)?It is a medication error 
(MESI)
Complete:
!SIF
!Medication Error form
both ≤ 14 calendar days
No additional 
forms 
to be completed
It is a medication error (MESI)
Complete:
!SIF
!Medication Error form
both ≤ 14 calendar daysYes
No
YesNoYes
No
AE: Adverse Event
SIF: Safety Information FormMESI: Medical Event of  Special Interest (medication errors)
All timelines are from the investigator’s first knowledge of the event
Figure 12–[ADDRESS_849173]-related S[LOCATION_003]Rs by [CONTACT_3454]:
Novo Nordisk will notify the investigator of trial product-related suspected unexpected serious 
adverse reactions (S[LOCATION_003]Rs) in accordance with local requirements and GCP.1In addition, the 
investigator will be informed of any trial-related SAEs that may warrant a change in any trial 
procedure.
In accordance with regulatory requirements, Novo Nordisk will inform the regulatory authorities, 
including European Medicines Agency (EMA), of trial product-related S[LOCATION_003]Rs. In addition, Novo 
Nordisk will inform the IRBs/IECs of trial product-related S[LOCATION_003]Rs in accordance with local 
requirement and GCP1, unless locally this is an obligation of the investigator.
Novo Nordisk products used as concomitant medication:
If a SAE and/or MESI is considered to have a causal relationship with a Novo Nordisk marketed 
product used as concomitant medication in the trial, it is important that the suspected relationship is 
reported to Novo Nordisk, e.g. in the alternative aetiology section on the safety information form. 
Novo Nordisk may need to report this adverse event to relevant regulatory authorities.
12.[ADDRESS_849174] be reported to Novo Nordisk according to the following:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 39 of 67
!SAEs: All SAEs must be followed until the outcome of the event is “recovered/resolved”, 
“recovered/resolved with sequelae” or “fatal”, and until all queries have been resolved. 
Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to 
another AE) may be closed with the outcome “recovering/resolving” or “not recovered/not 
resolved”. Cases can be closed with the outcome of “recovering/resolving” when the subject 
has completed the follow-up period and is expected by [CONTACT_36308].
The SAE follow-up information should only include new (e.g. corrections or additional) 
information and must be reported within 24 hours of the investigator´s first knowledge of 
the information. This is also the case for previously non-serious AEs which subsequently 
become SAEs. 
!Non-serious AEs leading to permanent treatment discontinuation : Non-serious AEs 
must be followed until the outcome of the event is “recovering/resolving”, 
“recovered/resolved” or “recovered/resolved with sequelae” or until the end of the follow-up 
period stated in the protocol, whichever comes first, and until all queries related to these 
AEs have been resolved. Cases of chronic conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may be closed with the outcome 
“recovering/resolving” or “not recovered/not resolved”. Cases can be closed with the 
outcome of “recovering/resolving” when the subject has completed the follow-up period and 
is expected by [CONTACT_36308].
!Non-serious AE fulfilling the MESI criteria: Non-serious AEs must be followed until the 
outcome of the event is “recovering/resolving”, “recovered/resolved” or “recovered/resolved 
with sequelae” or until the end of the follow-up period stated in the protocol, whichever 
comes first and until all queries related to these AEs have been resolved. Cases of chronic 
conditions, cancer or AEs ongoing at time of death (where death is due to another AE) may 
be closed with the outcome “recovering/resolving” or “not recovered/not resolved”. Cases 
can be closed with the outcome of “recovering/resolving” when the subject has completed 
the follow-up period and is expected by [CONTACT_36308].- Follow-up information 
on MESIs should only include new (e.g. corrections or additional) information and must be 
reported within 14 calendar days of the investigator’s first knowledge of the information. 
This is also the case for previously reported non-serious AEs which subsequently fulfil the MESI criteria. 
The investigator must ensure that the worst case severity and seriousness of an event is kept 
throughout the trial. A worsening of an unresolved AE must be reported as follow up with re-
assessment of severity and/or seriousness of the event.
Queries or follow-up requests from Novo Nordisk must be responded to within [ADDRESS_849175].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 40 of 67
12.4 Technical complaints and technical complaint samples
12.4.1 Reporting of technical complaints
All technical complaints on any of the following Novo Nordisk products:
!Victoza® 
!Needles for Liraglutide (Victoza®) prefilled pen-injector
!Repaglinid (NovoNorm®/Prandin®/ GlucoNorm®) tablet
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Center, Novo Nordisk.
All technical complaints on any non-Novo Nordisk OAD products:
!Alpha-glucosidase inhibitors
!DPP-4 inhibitors
!Meglitinides 
!SGLT-2 inhibitors
!Sulfonylureas  
!Thiazolidinediones
which occur from the time of first usage of the product until the time of the last usage of the 
product, must be collected and reported to Customer Complaint Center, Novo Nordisk. In addition 
the technical complaint should be reported to the Marketing Authorisation Holder via the pharmacy, 
or similar, where the product was obtained.
Contact [CONTACT_8972] (fax, e-mail and address) for reporting to Novo Nordisk are provided in Attachment 
I to the protocol.
The investigator must assess whether the technical complaint is related to any AEs, SAEs, and/or 
MESI.
Technical complaints must be reported on a separate technical complaint form. A technical 
complaint form for each batch or lot number must be completed.
The investigator must complete the technical complaint form in the eCRF within the following 
timelines of the trial site obtaining knowledge of the technical complaint:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 41 of 67
!Technical complaint assessed as related to an SAE within 24 hours
!All other technical complaints within [ADDRESS_849176] 
coordinate the shipment to Customer Complaint Center, Novo Nordisk (the address is provided in 
Attachment I)  and ensure that the sample is sent as soon as possible. A print or copy of the technical 
complaint form must be sent with the sample .
The investigator must ensure that the technical complaint sample contains the batch or lot number.
If the technical complaint sample is unobtainable, the investigator must specify on the technical 
complaint form why it is unobtainable. 
For non- Novo Nordisk OADs the sample should be returned to the Marketing Authorisation Holder 
via the pharmacy, or similar, where the product was obtained.
12.[ADDRESS_849177](s).
The investigator must follow the pregnancy until the pregnancy outcome and the newborn infant is 
one month of age.
The investigator must report information about the pregnancy, pregnancy outcome, and health of 
the newborn infant(s), as well as AEs in connection with the pregnancy, and AEs in the foetus and 
newborn infant.
The following must be collected and reported by [CONTACT_36309] - electronically 
(e.g. in PDF format), or by [CONTACT_36310]:CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 42 of 67
1) Reporting of pregnancy information
Information about the pregnancy and pregnancy outcome/health of the newborn infant(s) has to 
be reported on Maternal Form 1A and 1B, respectively. 
When the pregnancy outcome is abnormal (i.e. congenital anomalies, foetal death including 
spontaneous abortion and/or any anomalies of the foetus observed at gross examination or 
during autopsy), and/or when a congenital anomaly is diagnosed within the first month, further 
information has to be reported for the female subject on Maternal Form 2. In addition, 
information from the male partner has to be reported on the Paternal Form, after an informed 
consent has been obtained from the male partner. 
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator's first knowledge of initial or follow-up information. 
2) Reporting of AE information
The investigator has to report AEs in connection with the pregnancy as well as in the foetus and 
newborn infant(s). The SAEs that must be reported include abnormal outcome, such as foetal 
death (including spontaneous abortion), and congenital anomalies (including those observed at 
gross examination or during autopsy of the foetus), as well as other pregnancy complications 
fulfilling the criteria of an SAE.
Forms and timelines for reporting AEs:
Non-serious AEs: 
– Paper AE form* within 14 calendar days of the investigator's first knowledge of the initial 
or follow-up information to the non-serious AE.
SAEs: 
– Paper AE form* within 24 hours of the investigator's first knowledge of the SAE.
– Paper safety information form within 5 calendar days of the investigator's first knowledge 
of the SAE.
–SAE follow-up information to the AE form and/or safety information form within 24 
hours of the investigator's first knowledge of the follow-up information.
* It must be clearly stated in the AE diagnosis field on the AE form if the event occurred in 
the subject, foetus or newborn infant.
Any queries or follow-up requests from Novo Nordisk to non-serious AEs, SAEs and pregnancy 
forms must be responded to by [CONTACT_19452] [ADDRESS_849178].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 43 of 67
12.5.2 Pregnancies in female partners of male subjects (Applicable to US only)
Male subjects must be instructed to notify the investigator if their female partner becomes pregnant 
during the trial except in the screening period. At the last scheduled visit, male subjects must be 
asked if their female partner has become pregnant.
If a female partner has become pregnant during the trial, the investigator must follow-up on the 
pregnancy outcome and until the newborn infant is one month of age, irrespective of whether the 
trial is completed or not. The investigator must ask the male subject and assess, if the pregnancy 
outcome is normal or abnormal. 
When the pregnancy outcome is normal this information is recorded in the subject's medical record 
only, no further information is collected and reported to Novo Nordisk. When the pregnancy 
outcome is abnormal (i.e. congenital anomalies, foetal death including spontaneous abortion and/or 
any anomalies of the foetus observed at gross examination or during autopsy), the following must 
be reported by [CONTACT_136760] (e.g. in PDF format) or by [CONTACT_6791]:
1) Reporting of pregnancy information
Information from the male subject has to be reported on the Paternal Form. Furthermore, 
information from the female partner (including information about the pregnancy outcome and 
health status of the infant until the age of one month) has to be reported on the Maternal Forms 1A, 
1B and 2, after an informed consent has been obtained from the female partner. 
Initial reporting and follow-up information must be reported within 14 calendar days of the 
investigator's first knowledge of initial or follow-up information. 
2) Reporting of AE information
The following AEs in the foetus and newborn infant have to be reported:
!Non-serious AEs evaluated as possible/probably related to the father's treatment with the trial 
product(s). 
!SAEs in the foetus and newborn infant - whether or not related to the father's treatment with the 
trial product(s). This includes an abnormal outcome - such as foetal death (including 
spontaneous abortion) and congenital anomalies (including those observed at gross examination 
or during autopsy of the foetus).
Forms and timelines for reporting AEs:
Please see section 12.5.1 , point 2, "Forms and timelines for reporting AEs:". CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849179].
12.6 Precautions and/or overdose
When initiating treatment with Victoza®, the subject may, in some cases, experience loss of 
fluids/dehydration, e.g., in cases of vomiting, nausea or diarrhoea sometimes with a decrease in 
kidney function. It is important to avoid dehydration by [CONTACT_635623].
From clinical trials and marketed use, overdoses have been reported up to 40 times the 
recommended maintenance dose (72 mg). One case of a -fold overdose (  mg daily) given for  
has been reported. Generally, the patients reported severe nausea, vomiting and diarrhoea, 
but recovered without complications. None of the patients reported severe hypoglycaemia. In the 
event of overdose, appropriate supportive treatment should be initiated according to the patient’s 
clinical signs and symptoms.
For non Novo Nordisk marketed products please consult the EU summary of product characteristic 
and US prescribing information for information on precautions and/or overdose. 
12.7 Committees related to safety
12.7.1 Novo Nordisk safety committee
Novo Nordisk will constitute an internal Victoza®safety committee to perform ongoing safety 
surveillance.
[ADDRESS_849180] or an 
assessment has not been done and will not be available, or if the question is irrelevant (e.g. is not 
applicable), indicate this according to the data entry instructions.
The following will be provided as paper CRFs:
!Pregnancy forms
In addition paper AE forms, Safety information forms and Technical complaint forms will be 
provided. These must be used when access to the eCRF is revoked or if the eCRF is unavailable. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849181].
13.1 Corrections to case report forms 
Corrections to the eCRF data may be made by [CONTACT_36322]'s delegated staff.
An audit trail will be maintained in the eCRF application containing as a minimum: the old and the 
new data, identification of the person entering the data, date and time of the entry and reason for the 
correction.
If corrections are made by [CONTACT_093]'s delegated staff after the date the investigator has signed 
the case book, the case book must be signed and dated again by [CONTACT_093].
13.[ADDRESS_849182] ensure that data is recorded in the eCRF as soon as possible, preferably 
within 5 days after the visit. Once data has been entered, it will be available to Novo Nordisk for 
data verification and validation purposes.
Site specific eCRF data (in an electronic readable format) will be provided to the trial site before 
access to the eCRF is revoked. This data must be retained at the trial site.
[ADDRESS_849183] monitoring visit will be performed as soon as possible after FSFV at 
the trial site and no later than 4 weeks after. The monitoring visit intervals will depend on the 
outcome of the remote monitoring of the eCRFs, the trial site's recruitment rate and the compliance 
of the trial site to the protocol and GCP, but will not exceed [ADDRESS_849184] access to source documents (original documents, data and 
records) including documentation for pre-trial HbA 1c(see section 6.7). Direct access includes 
permission to examine, analyse, verify and reproduce any record(s) and report(s) that are important 
to the evaluation of the trial. If the electronic medical record does not have a visible audit trail, the 
investigator must provide the monitor with signed and dated printouts. In addition the relevant trial 
site staff should be available for discussions at monitoring visits and between monitoring visits (e.g.
by [CONTACT_756]).
All data must be verifiable in source documentation other than the eCRF.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849185] only be one source defined at any time for any data element.
Source data generated by [CONTACT_36323]; any correction must be explained, signed and dated 
by [CONTACT_36324].
The returned diaries must be filed with source documents.
The monitor will ensure that the CRFs are completed.
The following data will be source data verified for screening failures: 
!Date for obtaining informed consent
Monitors must review the subject's medical records and other source data (e.g. the diaries) to ensure 
consistency and/or identify omissions compared to the eCRF. If discrepancies are found, the 
investigator must be questioned about these.
A follow-up letter (paper or electronic) will be sent to the investigator following each monitoring 
visit. This should address any action to be taken.
[ADDRESS_849186] Operating Procedures and IT architecture documentation. The use and 
control of these systems are documented.
Investigators working on the trial may use their own electronic systems to capture source data. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 47 of 67
17 Statistical considerations
Results from the statistical analyses will generally be presented by [CONTACT_1192]-sided confidence intervals 
with a confidence level of 95%. 
The full analysis set (FAS) will be used in the analysis of the efficacy endpoints. For the safety 
endpoints, the safety analysis set (SAS) will be used. 
The main statistical analyses and summaries will be based on assessments taken while the subject is 
on treatment. With exception for AEs (see Section [IP_ADDRESS] ), the period in which a subject will be 
considered to be on treatment extends to one day after last administration of trial product.
Laboratory values below the lower limit of quantification (LLOQ) will be set to ½LLOQ.  
17.[ADDRESS_849187] a difference in the time to inadequate 
glycaemic control between the Victoza®arm and the OAD arm, using a two-sided log rank test at a 
5% significance level. The power is set to 90%.
The distributions of event time for the two treatment arms are derived from a model of the 
continuous HbA 1cmeasurements. In this model, the post-baseline measurements for each subject 
are assumed to be normally distributed and, conditional on a random subject effect, independent 
between assessment times. Based on data from another Novo Nordisk trial (NN2211-1860), the 
mean HbA 1cin the Victoza®arm is anticipated to be at a constant post-baseline level of 6.9% and 
the standard deviation of the within-subject error is anticipated to be 0.85%. The latter is in reality 
an estimate of the standard deviation of the total error and is therefore a conservative estimate of the 
within-subject standard deviation. 
A mean treatment difference in HbA 1cof 0.3% is considered clinically relevant and is therefore 
used as the assumption in the model18. The HbA 1clevels in the two treatment arms are assumed to 
diverge after the visit at 65 weeks, when the mean in the OAD arm is assumed to increase in one step from 6.9% to 7.2%. Otherwise, the means are assumed to be constant during the observation 
period between 26 and 104 weeks.
Based on previous trials, the anticipated percentage of subjects who discontinue treatment 
prematurely (are withdrawn from the trial) without having inadequate glycaemic control is 20% in 
both treatment arms. As a conservative assumption, these subjects are assumed to discontinue 
before the week [ADDRESS_849188] had inadequate glycaemic control after 104 weeks is 
66% in the Victoza
®arm and 76% in the OAD arm. The number of subjects who complete the trial CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 48 of 67
without premature treatment discontinuation (for any reason including inadequate glycaemic 
control) is expected to be 462.
In order to investigate the influence of the values of the model parameters on the calculation, 
sample sizes have been calculated for different alternative scenarios, assuming the mean post-
baseline HbA 1clevel in the Victoza®arm to be 6.8%, 6.9% or 7.0%, the standard deviation to be 
0.7% or 0.85%, the treatment difference to be 0.2% or 0.3% and the divergence time to be 52 or 65 
weeks. The results are presented in Table 17–1 with the adopted sample size marked in bold.
Table 17–1 Sample size calculations for different scenarios – total number of randomised 
subjects
Divergence time
[ADDRESS_849189] deviation
Mean HbA 1cin 
Victoza®armTreatment 
difference0.7% 0.85% 0.7% 0.85%
6.8% 0.2% 1138 1782 2394 3840
0.3% [PHONE_13230] 1636
6.9% 0.2% 1332 2042 2948 4608
0.3% [PHONE_13231] 1994
7.0% 0.2% 1668 2456 3948 5868
0.3% 752 1098 1736 2566
17.2 Definition of analysis sets
The following analysis sets are defined in accordance with the ICH-E9 guideline.
FAS: includes all randomised subjects who have received at least one dose and have any post 
randomisation data. The statistical evaluation of the FAS will follow the intention-to treat principle 
and subjects will contribute to the evaluation “as randomised”.
SAS: includes all subjects exposed to at least one dose of trial product. Subjects in the SAS will 
contribute to the evaluation “as treated”.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849190] be documented and 
signed by [CONTACT_36331]. The subjects and observations excluded from 
analysis sets, and the reason for this, will be described in the clinical trial report.
17.3 Primary endpoint
The primary endpoint is the time to inadequate glycaemic control defined as HbA 1c> 7.0% (53 
mmol/mol) at two scheduled consecutive visits after the first [ADDRESS_849191] possible occurrence is at week 38. 
The time to inadequate glycaemic control will be compared between the Victoza®arm and the OAD 
arm using a two-sided nonparametric test at a 5% significance level. The test will be a generalised 
log rank test for interval censored failure time data19. The analysis will not be based on any model 
assumptions such as proportional hazards. The possible event times will be considered as a discrete set of time points corresponding to the scheduled visits. An alternative but technically equivalent 
model would be to view the event time as a continuous variable which can only be observed to lie 
in the interval between the visit when inadequate glycaemic control is established and the previous 
scheduled visit. Subjects who complete the trial without an event of inadequate glycaemic control 
will be censored after the last visit at [ADDRESS_849192] p-value will be calculated.
17.4 Secondary endpoints
17.4.1 Supportive secondary endpoints
[IP_ADDRESS] Efficacy endpoints
Time to premature treatment discontinuation (for any reason including inadequate glycaemic 
control)CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849193] attended visit on treatment and the next 
planned visit.
Change from baseline in HbA 1cat 104 weeks or at premature treatment discontinuation
The change from baseline in HbA 1cwill be evaluated using an analysis of covariance (ANCOVA) 
model where the last post-baseline measurement taken on treatment will enter as the dependent 
variable, treatment arm and country as factors and baseline HbA 1c as a covariate. The estimated 
differences between Victoza®and OAD will be presented together with the corresponding 95% 
confidence intervals and two-sided p-values.
To further describe the effects of Victoza®compared to OAD with respect to the change from 
baseline in HbA 1c, supportive analyses will be performed using a mixed model for repeated 
measurements (MMRM) where all post-baseline measurements taken on treatment will enter as the 
dependent variable, treatment arm as a factor and baseline HbA 1c as a covariate. The factor and the 
covariate will be nested within visit. An unstructured covariance matrix for the measurements 
within subject will be employed. From this analysis, the differences between Victoza®and OAD at 
different visits will be estimated.
The purpose of the MMRM analysis is to estimate the treatment effects that would have been 
observed if all subjects had remained on treatment and completed all visits, instead of droppi[INVESTIGATOR_41248]. 
The analysis relies on the assumption that data are missing at random (MAR), which means that 
given the observed data, the events that lead to data being missing are independent of the 
unobserved data. This is a reasonable assumption also for subjects discontinuing treatment due to 
inadequate glycaemic control since it can be explained by [CONTACT_635624].
Categorical endpoints related to HbA 1c
Secondary categorical efficacy endpoints are subjects who at 104 weeks or at premature treatment 
discontinuation achieve (Yes/No):CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 51 of 67
!HbA 1c≤ 6.5%
!HbA 1c ≤ 7.0% without weight gain
!HbA 1c≤ 7.0% without treatment emergent severe hypoglycaemic epi[INVESTIGATOR_635601]
!HbA 1c ≤ 7.0% without weight gain and no tr eatment emergent severe hypoglycaemic 
epi[INVESTIGATOR_635602]. In the 
calculation of the responses, the last post-baseline measurements of HbA 1cand body weight which 
were taken on treatment will be used. The model will include treatment arm as a factor and baseline 
HbA 1cas a covariate. The results will be described by [CONTACT_635625]®
versus OAD and the associated 95% confidence interval and two-sided p-value.
Other efficacy endpoints
The change from baseline at 104 weeks or at premature treatment discontinuation will be evaluated 
for:
!FPG
!Body weight
!BMI
!Systolic and diastolic blood pressure
These endpoints will be analysed using the same type of ANCOVA as for HbA 1cbut with the 
baseline measurement of the corresponding endpoint as covariate instead of baseline HbA 1c. The 
corresponding supportive analyses to estimate treatment differences at different visits will also be performed. 
BMI will be derived at each visit with a body weight measurement by [CONTACT_635626].
[IP_ADDRESS] Safety endpoints
The following secondary endpoints are used to support the safety objectives: CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 52 of 67
!Number of severe hypoglycaemic epi[INVESTIGATOR_1841]
!Number of severe or blood glucose confirmed symptomatic hypoglycaemic epi[INVESTIGATOR_1841]
!Number of documented symptomatic hypoglycaemic epi[INVESTIGATOR_1841] (ADA)
!Number of SAEs
!Number of AEs leading to permanent discontinuation of trial product
!Change from baseline at 104 weeks or at premature treatment discontinuation:
oLipi[INVESTIGATOR_635603] (MedDRA) coding. A treatment emergent adverse event (TEAE) is defined as 
an event that has onset date (or increase in severity) on or after the first day of trial product 
administration and no later than seven days after the last day of trial product administration.
AE data will be displayed in terms of the number of subjects with at least one event, the percentage 
of subjects with at least one event, the number of events and the event rate per 1000 patient years of 
exposure. The main AE summaries will only contain TEAEs. Non-treatment emergent AEs will be 
included in listings and overview summaries. 
Hypoglycaemic epi[INVESTIGATOR_635604] a negative 
binomial regression model with the number of treatment emergent epi[INVESTIGATOR_635605], the 
logarithmic function as link function and the logarithm of the time period in which epi[INVESTIGATOR_635606]. The model will include treatment arm as factor and 
baseline HbA 1cas a covariate. The results will be described by [CONTACT_635627]®versus OAD and the associated 95% confidence interval and two-sided p-value.
The hypoglycaemic epi[INVESTIGATOR_635607] a similar way as the AEs in 
terms of the number of subjects with at least one event, the percentage of subjects with at least one 
event, the number of events and the event rate per 1000 patient years of exposure. 
Classification of Hypoglycaemia:
Treatment emergent: hypoglycaemic epi[INVESTIGATOR_215525], and no later than the day 
after the last day of trial product administration.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 53 of 67
Nocturnal hypoglycaemic epi[INVESTIGATOR_1841]: are epi[INVESTIGATOR_1841] o ccurring between 00:01 and 05.59 both inclusive.
Hypoglycaemic epi[INVESTIGATOR_513417] (see Figure 17–2 ) and the ADA classification of hypoglycaemia (see Figure 17–3 ).
Novo Nordisk classification of hypoglycaemia
In normal physiology, symptoms of hypoglycaemia occur below a plasma glucose level of 3.1 
mmol/L (56 mg/dL).21Therefore, Novo Nordisk has included hypoglycaemia with plasma glucose 
levels below this cut-off point in the defi nition of blood glucose (BG) confirmed hypoglycaemia.
Novo Nordisk uses the following classification (see Figure 17–2 ) in addition to the ADA 
classification:
!Severe hypoglycaemia according to the ADA classification22.
!Symptomatic BG confirmed hypoglycaemia: An epi[INVESTIGATOR_635608] < 3.1 mmol/L (56 mg/dL) with symptoms consistent with hypoglycaemia.
!Asymptomatic BG confirmed hypoglycaemia: An epi[INVESTIGATOR_635608] < 3.1 mmol/L (56 mg/dL) without symptoms consistent with hypoglycaemia.
!Severe or BG confirmed symptomatic hypoglycaemia: An epi[INVESTIGATOR_135528]22or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 
mg/dL) with symptoms consistent with hypoglycaemia. 
!BG confirmed hypoglycaemia: An epi[INVESTIGATOR_635609] a plasma glucose value 
< 3.1 mmol/L (56 mg/dL) with or without symptoms consistent with hypoglycaemia. 
!Severe or BG confirmed hypoglycaemia: An epi[INVESTIGATOR_635610]22or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/dL) with
or without symptoms consistent with hypoglycaemia. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 54 of 67
Figure 17–2 Novo Nordisk classification of hypoglycaemia 
ADA classification22of hypoglycaemia 
!Severe hypoglycaemia: An epis ode requiring assistance of another person to actively 
administer carbohydrate, glucagon, or take other corrective actions. Plasma glucose 
concentrations may not be available during an event, but neurological recovery following 
the return of plasma glucose to normal is considered sufficient evidence that the event was 
induced by a low plasma glucose concentration.
!Asymptomatic hypoglycaemia: An epi[INVESTIGATOR_36245], but with a measured plasma glucose concentration ≤ 3.9 mmol/L (70 
mg/dL).
!Documented symptomatic hypoglycaemia: An epi[INVESTIGATOR_36246] a measured plasma glucose concentration ≤ 3.9 mmol/L 
(70 mg/dL).
!Pseudo-hypoglycaemia: An epi[INVESTIGATOR_36247] a measured plasma glucose concentration > 3.9 
mmol/L (70 mg/dL) but approaching that level.
!Probable symptomatic hypoglycaemia: An epi[INVESTIGATOR_135529] a plasma glucose determination but that was 
presumably caused by a plasma glucose concentration ≤ 3.9 mmol/L (70 mg/dL).CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 55 of 67
Figure 17–3 ADA classification of hypoglycaemia 
Laboratory assessments
Lipi[INVESTIGATOR_805], biochemistry and haematology will be summarised and evaluated by [CONTACT_9086]. 
Amylase and lipase will be analysed with the same type of statistical methods as for HbA 1cbut with 
the baseline value of the corresponding endpoint as covariate instead of baseline HbA 1c. The 
response as well as the baseline value will be log transformed in the analysis.
eGFR will be derived from serum creatinine using the modification of diet in renal disease (MDRD) 
formula.
Pulse
Pulse will be summarised descriptively as well as analysed with the same type of statistical methods 
as for HbA 1cbut with baseline pulse as covariate instead of baseline HbA 1c.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849194] been defined in order to ensure that subjects are eligible for 
trial participation. Furthermore, a withdrawal criterion has been defined to ensure that subjects that 
in whom glycaemic treatment intensification may be warranted are withdrawn from the trial.
All subjects included in the trial will continue their pre-trial treatment with metformin throughout 
the trial. During the trial, Victoza®or a marketed OAD will be added. All trial medications have 
been approved and have shown efficacy in lowering blood glucose levels. It is expected that the 
majority of subjects entering the trial will achieve an improved glucose control during the trial.
The trial drugs may be associated with AEs, but relevant precautions have been implemented in the 
design and planned conduct of the trial in order to minimise the risks and inconveniences of 
participating in the trial. Furthermore, subjects will be fully informed about possible AEs and 
inconveniences and will be instructed to contact [CONTACT_635628].
Safety information on Victoza®can be found in the approved local label for Victoza®. Safety 
information of the OADs used in this trial can be found in the approved local label of the individual 
OAD. 
The subjects have the right to withdraw from the trial at any time, without giving a specific reason. 
Novo Nordisk will be entitled to keep the data collected.
It is concluded that the potential benefits from participating in the trial outweigh the potential risks. 
18.[ADDRESS_849195] comply with applicable 
regulatory requirement(s) and adhere to ICH GCP2and the requirements in the Declaration of 
Helsinki3.
Before any trial-related activity, the investigator must give the subject verbal and written 
information about the trial and the procedures involved in a form that the subject can read and 
understand. This includes the use of an impartial witness where required according to local 
requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849196]’s willingness to continue 
participating in the trial, the investigator must inform the subject in a timely manner, and a revised 
written subject information must be provided and a new informed consent must be obtained.
18.[ADDRESS_849197]’s data will be handled 
as follows:
!Data already collected and data collected at the end-of-trial visit will be retained by [CONTACT_49753], entered into the database and used for the trial report. 
!Safety events will be reported to Novo Nordisk and regulatory authorities according to 
local/national requirements.
If data is used, it will always be in accordance with local regulations and IRBs/IECs.
18.[ADDRESS_849198] be sent to IRB/IEC for approval/favourable opi[INVESTIGATOR_17950].
18.5 Premature termination of the trial and/or trial site
Novo Nordisk, the IRBs/IECs or a regulatory authority may decide to stop the trial, part of the trial 
or a trial site at any time, but agreement on procedures to be followed must be obtained.
If a trial is suspended or prematurely terminated, the investigator must inform the subjects promptly 
and ensure appropriate therapy and follow-up. The investigator and/or Novo Nordisk must also 
promptly inform the regulatory authorities and IRBs/IECs and provide a detailed written 
explanation. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849199] be 
provided to the IRBs/IECs in case it has an impact on the planned follow-up of subjects who have 
participated in the trial. If it has an impact, the actions needed to inform and protect the subjects 
should be described.
[ADDRESS_849200] be documented and explained in a protocol deviation by [CONTACT_18030], date, 
and the action(s) taken. Some deviations, for which corrections are not possible, can be 
acknowledged and confirmed via edit checks in the eCRF or via listings from the clinical database. 
Documentation on protocol deviations must be kept in the investigator's trial master file and 
sponsor trial master file.
[ADDRESS_849201] to audits conducted by [CONTACT_36341]/IECs. Audits and inspections may 
take place during or after the trial. The investigator and the site staff as well as Novo Nordisk staff 
have an obligation to cooperate and assist in audits and inspections. This includes giving auditors 
and inspectors direct access to all source documents and other documents at the trial site relevant to 
the clinical trial. This includes permission to examine, analyse, verify and reproduce any record(s) 
and report(s) that are relevant to the evaluation of the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849202] be available 
to Novo Nordisk:
!Regulatory approval and/or acknowledgement of notification as required 
!Approval/favourable opi[INVESTIGATOR_36254]/IECs clearly identifying the documents reviewed as 
follows: protocol, any protocol amendments, subject information/informed consent form, 
any other written information to be provided to the subject and subject recruitment materials
!List of IRB/IEC members and/or constitution (or a general assurance number/statement of 
compliance)
!Curricula vitae of investigator and sub-investigator(s) (current, dated and signed - must 
include documented GCP training or a certificate)
!Signed receipt of Investigator’s brochure (if applicable), signed receipt of Victoza®SmPC
or similar labelling (according to local regulations)
!Signed and dated Agreement on Protocol
!Signed and dated agreement on protocol amendment, if applicable
!Contract, signed by [CONTACT_1755]/or appropriate parties on behalf of the investigator’s 
site and Novo Nordisk
!Source document agreement
!Central laboratory certification and normal ranges
!Insurance statement, if applicable
!Financial disclosure form from investigator and sub-investigator(s)
Only applicable for US trial sites: 
!For US trial sites: verification under disclosures per Code of Federal Regulations (CFR) of 
Financial Conflict of Interest
!For US trial sites: FDA form [ADDRESS_849203] be completed and signed by [CONTACT_635629]: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 60 of 67
FDA form 1572:
For US sites
!Intended for US sites
!Conducted under the IND
!All US investigators, as described above, will sign FDA Form 1572
For sites outside the US:
!Intended for participating sites outside of the US
!Not conducted under the IND
!All investigators outside of the US will not sign FDA form 1572
Novo Nordisk will analyse and report data from all sites together.
By [CONTACT_12142], each investigator agrees to comply fully with ICH GCP2, applicable 
regulatory requirements and the Declaration of Helsinki3. 
By [CONTACT_12142], each investigator also agrees to allow Novo Nordisk to make investigator's 
name [CONTACT_136821] 
[CONTACT_36344].
[ADDRESS_849204] of the trial at his/her site. If any tasks are delegated, 
the investigator must maintain a log of appropriately qualified persons to whom he/she has 
delegated specified trial-related duties. The investigator must ensure that there is adequate training 
for all staff participating in the conduct of the trial. It is the investigator's responsibility to supervise 
the conduct of the trial and to protect the rights, safety, and well-being of the subjects.
A qualified physician, who is an investigator or a sub-investigator for the trial, must be responsible 
for all trial-related medical decisions.
The investigator must ensure adequate supervision of the conduct of the trial at the trial site. 
The investigator will follow instructions from Novo Nordisk when processing data.
The investigator is responsible for filing essential documents (i.e. those documents which 
individually and collectively permit evaluation of the conduct of a trial and the quality of the data
produced) in the investigator trial master file. The documents including the subject identification 
code list should be kept in a secure locked facility, so no unauthorized persons can get access to the 
data. CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849205] delegate responsibility for medical care of 
subjects to a specific qualified physician who will be readily available to subjects during that time.
If the investigator is no longer able to fulfil the role as investigator (e.g. if he/she moves or retires), 
a new investigator will be appointed in consultation with Novo Nordisk. 
The investigator and other site personnel must have sufficient English skills according to their 
assigned task(s).
[ADDRESS_849206], if deemed necessary by [CONTACT_3454]. Provided that certain 
conditions are fulfilled, Novo Nordisk may grant access to information obtained during this trial to 
researchers who require access for research projects studying the same disease and/or trial product 
studied in this trial.
Novo Nordisk may publish on its clinical trials website a redacted clinical trial report for this trial.
One investigator will be appointed by [CONTACT_41170] 
(signatory investigator) on behalf of all participating investigators. The signatory investigator will 
be appointed based upon the criteria defined by [CONTACT_36346]23.
23.[ADDRESS_849207] submission with a poster or oral presentation at a scientific meeting, or CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 62 of 67
disclosure by [CONTACT_11174]. Novo Nordisk reserves the right to defer the release of data until 
specified milestones are reached, for example when the clinical trial report is available. This 
includes the right not to release the results of interim analyses, because the release of such 
information may influence the results of the entire trial. At the end of the trial, one or more 
scientific publications may be prepared collaboratively by [CONTACT_093](s) and Novo Nordisk. 
Novo Nordisk reserves the right to postpone publication and/or communication for up to [ADDRESS_849208] for 
Clinical Trial Disclosure13.
In all cases the trial results will be reported in an objective, accurate, balanced and complete manner, with a discussion of the strengths and limitations. All authors will be given the relevant 
statistical tables, figures, and reports needed to evaluate the planned publication. In the event of any 
disagreement on the content of any publication, both the investigators' and Novo Nordisk opi[INVESTIGATOR_36255].
Novo Nordisk will analyse and report data from all sites together. In a multi-centre trial, any 
publication of results in a journal article must acknowledge all trial sites. Where required by [CONTACT_635630], the investigator from each trial site will be named in an acknowledgement or in the 
supplementary material, as specified by [CONTACT_18038]. 
Novo Nordisk maintains the right to be informed of plans by [CONTACT_36347], presentation, communication or other information concerning the 
investigation described in this protocol. Any such communication must be submitted in writing to 
Novo Nordisk before submission for comments. Comments will be given within four weeks from 
receipt of the planned communication.
23.1.1 Authorship
Authorship of publications should be in accordance with the Uniform Requirements of the 
International Committee of Medical Journal Editors
23(sometimes referred to as the Vancouver 
Criteria).
23.1.2 Site-specific publication(s) by [CONTACT_1697](s)
For a multi-centre clinical trial, analyses based on single-site data usually have significant statistical 
limitations and frequently do not provide meaningful information for healthcare professionals or 
subjects, and therefore may not be supported by [CONTACT_3454]. It is a Novo Nordisk policy that 
such individual reports do not precede the primary manuscript and should always reference the 
primary manuscript of the trial.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: [ADDRESS_849209] their own research subjects' data, and will be 
provided with the randomisation code after results are available.
[ADDRESS_849210]'s medical records must be kept for the maximum period permitted by [CONTACT_5035][INVESTIGATOR_307], 
institution or private practice.
The investigator must agree to archive the documentation (this includes both electronic and paper-
based records) pertaining to the trial in an archive after completion or discontinuation of the trial if 
not otherwise notified. The investigator should not destroy any documents without prior permission 
from Novo Nordisk. If the investigator cannot archive the documents at the trial site, Novo Nordisk 
can refer the investigator to an independent archive provider that has a system in place to allow only 
the investigator to access the files.
The investigator must be able to access his/her trial documents without involving Novo Nordisk in 
any way. Site-specific CRFs and other subject data (in an electronic readable format or as paper 
copi[INVESTIGATOR_17951]) will be provided to the investigator before access is revoked to the systems 
supplied by [CONTACT_3454]. These data must be retained by [CONTACT_21655]. If the provided data (e.g.
the CD-ROM) is not readable during the entire storage period, the investigator can request a new 
copy. A copy of all data will be stored by [CONTACT_3454].
Novo Nordisk will maintain Novo Nordisk documentation pertaining to the trial for as long as the 
product is on the market plus 20 years. 
The files from the trial site/institution must be retained for 15 years after the completion of the trial, 
or longer if required by [CONTACT_36348]. In any case trial files cannot be 
destroyed until the trial site/institution is notified by [CONTACT_3454]. The deletion process must 
ensure confidentiality of data and must be done in accordance with local regulatory requirements.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 64 of 67
25 Institutional Review Boards/Independent Ethics Committees and 
regulatory authorities
IRB/IEC:
Written approval or favourable opi[INVESTIGATOR_36256]/IEC prior to commencement of 
the trial.
During the trial, the investigator or Novo Nordisk, as applicable, must promptly report the 
following to the IRB/IEC, in accordance with local requirements: updates to Investigator's Brochure
or Victoza®SmPC or similar labelling, unexpected SAEs where a causal relationship cannot be 
ruled out, protocol amendments according to local requirements, deviations to the protocol 
implemented to eliminate immediate hazards to the subjects, new information that may affect 
adversely the safety of the subjects or the conduct of  the trial (including new benefit-risk analysis in 
case it will have an impact on the planned follow-up of the subjects), annually written summaries of 
the trial status, and other documents as required by [CONTACT_1036]/IEC.
The investigator must ensure submission of the clinical trial report synopsis to the IRB/IEC.
Protocol amendments must not be implemented before approval or favourable opi[INVESTIGATOR_36257], unless necessary to eliminate immediate hazards to the subjects.
The investigator must maintain an accurate and complete record of all submissions made to the 
IRB/IEC. The records must be filed in the investigator trial master file and copi[INVESTIGATOR_36258].
Regulatory Authorities:
Regulatory authorities will receive the clinical trial application, protocol amendments, reports on 
SAEs, and the clinical trial report according to national requirements.
[ADDRESS_849211] liability for its products, and liability as assumed under the special laws, acts and/or guidelines for conducting clinical trials in any country, unless others have shown 
negligence.
Novo Nordisk assumes no liability in the event of negligence, or any other liability of the sites or 
investigators conducting the trial, or by [CONTACT_18033].CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 65 of 67
Novo Nordisk accepts liability in accordance with:
Russia: Federal Law of 12 April 2010 No. 61-FZ "On Medicinal Drugs' Circulation" and the Civil 
Code of the Russian Federation.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 66 of 67
27 References
1 Definition of primary care. American Academy of Family Physicians (AAFP) 
(http://www.aafp.org/about/policies/all/primary-care.html).  2015. 
2 ICH Harmonised Tripartite Guideline. International Conference on Harmonisation. ICH 
Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6 (R1), Step 4. 10-Jun-1996. 1996.
[ADDRESS_849212] 2013. 2013.
4 Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al. Efficacy and Safety 
Comparison of Liraglutide, Glimepi[INVESTIGATOR_14956], and Placebo, All in Combination With Metformin, in Type 2 Diabetes. Diabetes Care 2009; 32(1):84-90.
5 Davies M, Atkin S, Bavin SC, Scott D., Rossing P, Shamkhalova M et al. Efficacy and Safety 
of Liraglutide vs. Placebo as Add-on to Existing Diabetes Medication in Subjects with Type 2 Diabetes (T2DM) and Moderate Renal Impairment (LIRA-RENAL). Diabetes 2014; 63(Supplement 1):A212-A343.
6 Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. The 
American Journal of Medicine 2005; 118(5, Supplement):27-34.
7 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management 
of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015; 58(3):429-442.
8 Buteau J, Foisy S, Joly E, Prentki M. Glucagon-Like Peptide 1 Induces Pancreatic +¦-Cell 
Proliferation Via Transactivation of the Epi[INVESTIGATOR_14907]. Diabetes 2003; 52(1):124-132.
9 Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di MU et al. Glucagon-like peptide-1 
promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143(11):4397-4408.
10 Retnakaran R, Kramer CK, Choi H, Swaminathan B, Zinman B. Liraglutide and the 
Preservation of Pancreatic +¦-Cell Function in Early Type 2 Diabetes: The LIBRA Trial. Diabetes Care 2014; 37(12):3270-3278.
11 Wilson S, Delaney BC, Roalfe A, Roberts L, Redman V, Wearn AM et al. Randomised 
controlled trials in primary care: case study. BMJ 2000; 321(7252):24-27.CONFIDENTIAL
Protocol
CONFIDENTIALDate: 04 September 2015 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT no.: 2015-002417-29 Page: 67 of 67
12 Chalkidou K, Tunis S, Whicher D, Fowler R, Zwarenstein M. The role for pragmatic 
randomized controlled trials (pRCTs) in comparative effectiveness research. Clinical Trials 2012; 9(4):436-446.
13 Novo Nordisk. http://www.novonordisk-trials.com/website/content/how-we-disclose-trial-
information.aspx.  2015. 
14 De Angelius C., Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R et al. Clinical Trial 
Registration: A statement from the International Committee of Medical Journal Editors. N Engl J Med 2004; 351:1250-1251.
[ADDRESS_849213] 2007.16 The European Parliament and the Council of the European Council. Directive 2001/20/EC of 
the European Parliament and of the Council of [ADDRESS_849214] of clinical trials on medicinal products for human use, article 11. Official Journal of the European Communities May 2001.
17 The European Parliament and the Council of the European Council. Regulation (EC) No 
726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, article 57. Official Journal of the European Communities April 2001.
18 Guidance (draft) for Industry Diabetes Mellitus: Developi[INVESTIGATOR_234466]. Food and Drug Administration, February 2008.  
[ADDRESS_849215] Med 1996; 15(13):1387-1395.
[ADDRESS_849216] 1987; 79(3):777-781.
[ADDRESS_849217] ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L. et al. Hypoglycemia and 
Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine 
Society. Diabetes Care 2013; 36:1384-1395.
[ADDRESS_849218], 
Reporting, Editing and Publication of Scholarly Work in Medical Journals. Dec 2014.CONFIDENTIAL
Global and country key Novo Nordisk staff
Attachments I and II (if applicable) to the protocol are located in the Trial Master File.
Content: Global key staff and Country key staffCONFIDENTIALDate: Novo Nordisk
Version:
Status:Liraglutide
Trial ID: NN2211-4232 
Clinical Trial Report 
Appendix 16.1.1 January 2020
1.0
FinalCONFIDENTIAL
Protocol Amendment 1
CONFIDENTIALDate: 30 May 2016 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT No.: 2015-002417-29 Page: 1 of 6
Protocol Amendment
no 1
to Protocol, final version 1
dated 04 September 2015
Trial ID:NN2211-4232
LIRA-PRIME: Efficacy in controlling glycaemia with Victoza®(liraglutide) as add-on to 
metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects 
with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a 
primary care setting
Trial phase: 4
Applicable to all countries
Amendment originator:
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment 1
CONFIDENTIALDate: 30 May 2016 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT No.: 2015-002417-29 Page: 2 of 6
Table of Contents   
Page
Table of Contents.............................................................................................................. ................................2
Table of Figures............................................................................................................... .................................2
1 Introduction including rationale for the protocol  amendment .............................................................3
2 Changes ....................................................................................................................... ...............................3
2.1 Table of Contents........................................................................................................... ................3
2.2 Section 5.1 Type of trial ................................................................................................... .............3
2.3 Section 6.2 Inclusion criteria .............................................................................................. ...........3
2.4 Section 6.7 Pre-trial HbA 1c............................................................................................................4
2.5 Section 8.2.1 Concomitant illne ss and medical history .................................................................4
2.6 Section 9.1 Trial products.................................................................................................. ............4
2.7 Section 9.2 Labelling ....................................................................................................... ..............4
2.8 Section 9.4 Drug accountability  and destruction ...........................................................................4
2.9 Section 12.2 Reporting of adverse events.................................................................................... ..4
2.10 Section 12.2 Reporting of adverse events................................................................................... ...5
2.11 Section 17.1 Samp le size calculation....................................................................................... ......6
2.12 Section 17.2 Definiti on of analysis sets................................................................................... ......6
2.13 Section 17.3 Primary endpoint.............................................................................................. .........6
2.14 Section 17.3 Primary endpoint.............................................................................................. .........6
Table of Figures   
Page
Figure 12.1 Initial repor ting of AEs ........................................................................................... ........................5CONFIDENTIAL
Protocol Amendment 1
CONFIDENTIALDate: 30 May 2016 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT No.: 2015-002417-29 Page: [ADDRESS_849219] exceeded the expi[INVESTIGATOR_5695]. In addition this amendment will include 
clarifications of the randomisation ratio, sample size calculation and specific statistical analyses in 
line with suggestions from FDA.
Columbia has been included in the trial after the finalisation date of protocol version 1.0 and 
therefore country specific issues for Columbia has been added.
Finally, this protocol amendment will include updates and clarifications to wordings that may be 
confusing in their current form. This includes removal of a sentence in protocol section 6.7, 
rewording of section 8.2.1, updating figure 12.1 describing the initial reporting of AEs to align this
with the remaining text in the protocol and other minor changes. 
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
2 Changes
2.1 Table of Contents
Attachment II – Country list of key staff and relevant departments
2.2 Section 5.1 Type of trial
Subjects will be randomised in a 1:1 manner to one of two treatment arms: Victoza®or OAD.
2.3 Section 6.2 Inclusion criteria
4. Stable daily dose of metformin as monotherapy ≥ 1500 mg or maximum tolerated dose within for
≥60 days prior to the screening visit.CONFIDENTIAL
Protocol Amendment 1
CONFIDENTIALDate: 30 May 2016 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT No.: 2015-002417-29 Page: [ADDRESS_849220] be obtained prior to performing any trial related HbA 1cmeasurement.
2.5 Section 8.2.1 Concomitant illness and medical history
Procedures and assessments performed at visit 1 and/or [ADDRESS_849221] be reported in the 
diabetes module.   All other Rrelevant concomitant illness/medical history not related to diabetes 
should be transcribed to the eCRF. entered in the concomitant illness/medical history module.
2.[ADDRESS_849222] by [CONTACT_36705]. At each 
visit (except for visit number 3) the I investigator will prescribe trial product and at the next visit the 
subject will return to the site used, andpartly used and not used trial products including empty 
packaging material dispensed from the pharmacy. Subjects are allowed to keep partly used and 
unused trial products. At the site it will be documented what was prescribed and what the subject 
returned to the investigator at the next visit. 
Through this procedure the investigator can verify that correct trial product has been dispensed. 
Subjects are instructed to return all used, partly used and unused trial product including empty 
packaging material at the latest at their final site visit.
Applicable for Canada, Columbia, India, Latvia, Lebanon, Russia, Serbia and Turkey 
2.9 Section 12.2 Reporting of adverse events
!Company core data sheet (CCDS), Victoza®, 6.0 mg/mL, version 17.0 or any updates thereto
!Company core data sheet (CCDS) for Novo Nordisk A/S OAD: NovoNorm®/GlucoNorm®, 
version 13.0 or any updates thereto.CONFIDENTIAL
Protocol Amendment 1
CONFIDENTIALDate: 30 May 2016 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT No.: 2015-002417-29 Page: 5 of 6
!Non Novo Nordisk A/S marketed products: European summary of product characteristics or
other relevant labelling, current version or any updates thereto.
2.10 Section 12.2 Reporting of adverse events
Figure 12.1 Initial reporting of AEs 
(Old figure 12.1)
An AE is 
observed and 
reported It is an SAEcomplete:
!AE form ≤ 24 hours
!SIF ≤ 5 calendars days
It is a non-serious AE
complete:
!AE formFulfilling 
seriousness 
criteria?
MESI 
(medication 
error)?MESI 
(medication 
error)?It is a medication error 
(MESI)
Complete:
!SIF
!Medication Error form
both ≤ 14 calendar days
No additional 
forms to be completed
It is a medication error 
(MESI)
Complete:!SIF
!Medication Error form
both ≤ 14 calendar daysYes
No
YesNoYes
No
AE: Adverse Event
SIF: Safety Information Form
MESI: Medical Event of  Special Interest (medication errors)
All timelines are from the investigator’s first knowledge of the event
(Updated figure 12.1)
An AE is 
observed and 
reported It is an SAE
Complete:
!AE form ≤ 24 hours
!SIF ≤ 5 calendars days
It is a non-serious AE 
leading to permanent 
treatment 
discontinuation 
Complete:!AE formFulfilling 
seriousness 
criteria?
MESI 
(medication 
error)?MESI 
(medication 
error)?It is a medication error 
(MESI)
Complete:
!Medication Error form
   ≤ 14 calendar days
No additional 
forms 
to be completed
It is a medication error (MESI)
Complete:
!SIF
!Medication Error form
both ≤ 14 calendar daysYes
No
YesNoYes
No
AE: Adverse Event
SIF: Safety Information Form
MESI: Medical Event of Special Interest (medicat ion errors)
All timelines are from the investiga tor’s first knowledge of the eventCONFIDENTIAL
Protocol Amendment 1
CONFIDENTIALDate: 30 May 2016 Novo Nordisk
Trial ID: NN2211-4232 Version: 1.0
UTN: U1111-1170-7035 Status: Final
EudraCT No.: 2015-002417-29 Page: [ADDRESS_849223] had inadequate glycaemic control after 104 
weeks is [ZIP_CODE]% in the Victoza® arm and [ZIP_CODE]% in the OAD arm. In each arm, 200 subjects are 
expected to discontinue treatment prematurely without having inadequate glycaemic control . The 
number of subjects who complete the trial without premature treatment discontinuation (for any 
reason including inadequate glycaemic control) is expected to be 462.
2.12 Section 17.2 Definition of analysis sets
FAS: includes all randomised subjects who have received at least one dose and have any post 
randomisation data. The statistical evaluation of the FAS will follow the intention-to-treat principle 
and subjects will contribute to the evaluation “as randomised”.
2.[ADDRESS_849224] has an HbA 1cmeasurement above 7.0% at the week [ADDRESS_849225] visit 
which they attended while on treatment. In particular, subjects changing antidiabetic drug after 
randomisation will be discontinued from the trial and in relation to the primary endpoint be 
considered as censored and not having had an event of inadequate glycaemic control.CONFIDENTIAL
Protocol Amendment US_1
CONFIDENTIALDate: 18 January 2017 Novo Nordisk
Trial ID: NN2211-4232 Version: 2.0_US
UTN: U1111-1170-7035 Status: Final
EudraCT No.: 2015-002417-29 Page: 1 of 3
Protocol Amendment Local US
no 2
to Protocol, final version 2.0
dated 01 June 2016
Trial ID:NN2211-4232
LIRA-PRIME: Efficacy in controlling glycaemia with Victoza®(liraglutide) as add-on to 
metformin vs. OADs as add-on to metformin after up to 104 weeks of treatment in subjects 
with type 2 diabetes inadequately controlled with metformin monotherapy and treated in a 
primary care setting
Trial phase: 4
Applicable to US only
Amendment originator:
Clinical Trial Management
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.CONFIDENTIAL
This confidential document is the property of Novo Nordisk. No unpublished information contained herein may be 
disclosed without prior written approval from Novo Nordisk. Access to this document must be restricted to relevant 
parties.
Protocol Amendment US_1
CONFIDENTIALDate: 18 January 2017 Novo Nordisk
Trial ID: NN2211-4232 Version: 2.0_US
UTN: U1111-1170-7035 Status: Final
EudraCT No.: 2015-002417-29 Page: 2 of 3
Table of Contents   
Page
Table of Contents............................................................................................................... ...............................2
1 Introduction including rationale for the protocol  amendment .............................................................3
2 Changes ....................................................................................................................... ...............................3
2.1 Section 6.7 Pre-trial HbA1c.................................................................................................. .........3CONFIDENTIAL
Protocol Amendment US_1
CONFIDENTIALDate: 18 January 2017 Novo Nordisk
Trial ID: NN2211-4232 Version: 2.0_US
UTN: U1111-1170-7035 Status: Final
EudraCT No.: 2015-002417-29 Page: [ADDRESS_849226] an HbA 1c
reading measured and evaluated prior to screening.
In this protocol amendment:
!Any new text is written in italics.
!Any text deleted from the protocol is written using strike through.
[ADDRESS_849227] meets inclusion criterion 5, the requirements for documentation
are:
!The most recent available HbA 1cobtained by a health care professional and documented in
the medical records.
!Only HbA 1cmeasured within the last [ADDRESS_849228] be available and 
evaluated prior to screening.CONFIDENTIAL